Compare · CI vs CNTG
CI vs CNTG
Side-by-side comparison of The Cigna Group (CI) and Centogene N.V. (CNTG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and CNTG operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.25B, about 838.9x CNTG ($93.3M).
- CI has hit the wire 4 times in the past 4 weeks while CNTG has been quiet.
- CI has more recent analyst coverage (25 ratings vs 1 for CNTG).
- Company
- The Cigna Group
- Centogene N.V.
- Price
- $295.88+0.30%
- $0.56+86.47%
- Market cap
- $78.25B
- $93.3M
- 1M return
- +2.39%
- -
- 1Y return
- -4.59%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 1
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest CNTG
- CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
- CENTOGENE Announces Voting Results of Extraordinary General Meeting
- CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
- CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
- SEC Form 6-K filed by Centogene N.V.
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
- Centogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.